Intercell and Merck: Strategic alliance to develop monoclonal antibodies for the treatment of Staphylococcus aureus infections
Intercell AG announced that it has entered into a strategic partnership with Merck & Co., Inc. to develop human monoclonal antibodies against severe infections caused by Staphylococcus aureus, a bacterium, that causes severe hospitalacquired infections and has become increasingly resistant to a variety of antibiotics.
Under the terms of an agreement signed in May 2004, Merck has exercised an option to receive worldwide rights to develop and commercialize antibodies directed against proprietary antigens that have been detected by Intercell's Antigen Identification Program (AIP®). This technology identifies antibacterial targets. Pursuant to the agreement, Merck Inc. is responsible for subsequent preclinical and clinical development, registration and marketing of the product.
Intercell is entitled to an option exercise fee and additional milestone payments. Furthermore, Intercell will receive royalties on future sales of the product. There are no further costs involved for Intercell.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous